D5W

DRUG5 trials

Sponsors

Beth Israel Deaconess Medical Center, Shaare Zedek Medical Center, The University of Texas Health Science Center at San Antonio, Bristol-Myers Squibb, Henry Ford Health System

Conditions

Focal Segmental GlomerulosclerosisInsulin SensitivityMinimal Change DiseaseNephrotic SyndromePatent Ductus ArteriosusRenal ColicSeptic Shock

Phase 1

Thiamine as a Metabolic Resuscitator in Septic Shock

CompletedNCT01070810

Beth Israel Deaconess Medical CenterSeptic Shock

Start: 2010-02-28End: 2014-11-30Updated: 2017-05-15

Phase 2

Paracetamol and Patent Ductus Arteriosus (PDA)

Shaare Zedek Medical CenterPatent Ductus Arteriosus

Start: 2012-04-30Target: 80Updated: 2012-12-19

The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects

TerminatedNCT02267317

The University of Texas Health Science Center at San AntonioInsulin Sensitivity

Start: 2015-01-31End: 2018-09-30Updated: 2020-03-04

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

CompletedNCT02592798

Bristol-Myers SquibbFocal Segmental Glomerulosclerosis, Minimal Change Disease, Nephrotic Syndrome

Start: 2016-03-09End: 2020-01-28Updated: 2021-03-05

Unknown Phase

Efficacy of Magnesium Sulfate on Reducing Renal Colic in the Emergency Department

CompletedNCT03617289

Henry Ford Health SystemRenal Colic

Start: 2016-01-31End: 2016-05-31Updated: 2023-03-24

Related Papers

Thiamine administration in septic shock: a post hoc analysis of two randomized trials.

2024-02-0613 citations

Effect of acute TLR4 inhibition on insulin resistance in humans

Journal of Clinical Investigation2022-09-0615 citations